New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab

Olivier Bylicki,1 Nicolas Paleiron,2 Gaëlle Rousseau-Bussac,3 Christos Chouaïd3 1Pneumology Department, Hôpital d’Instruction des Armées Percy, Paris, 2Respiratory Department, Hôpital d’Instruction des Armées Saint-Anne...

Full description

Bibliographic Details
Main Authors: Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C
Format: Article
Language:English
Published: Dove Medical Press 2018-07-01
Series:OncoTargets and Therapy
Subjects:
pembrolizumab
immune-checkpoint inhibitor
NSCLC
PD-L1
Online Access:https://www.dovepress.com/new-pdl1-inhibitors-for-non-small-cell-lung-cancer-focus-on-pembrolizu-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/new-pdl1-inhibitors-for-non-small-cell-lung-cancer-focus-on-pembrolizu-peer-reviewed-article-OTT

Similar Items